Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Phase 1 Completed 30 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a two part phase I study in Japanese patients that will determine the safety, tolerability and pharmacokinetics of pazopanib monotherapy and of pazopanib in combination with lapatinib.

Timeline

Start: 2007-09-10
Primary completion: 2010-08-30
Completion: 2015-10-14

Publications

Inada-Inoue M, Ando Y, Kawada K, Mitsuma A, Sawaki M, Yokoyama T, Sunakawa Y, Ishida H, Araki K, Yamashita K, Mizuno K, Nagashima F, Takekura A, Nagamatsu K, Sasaki Y. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2014 Apr;73(4):673-83. doi: 10.1007/s00280-014-2374-3. Epub 2014 Jan 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapatinib	Small molecule	1000 mg	Oral
Subject	Lapatinib	Small molecule	1250 mg	Oral
Subject	Lapatinib	Small molecule	1500 mg	Oral
Subject	Pazopanib	Small molecule	400 mg	Oral
Subject	Pazopanib	Small molecule	600 mg	Oral
Subject	Pazopanib	Small molecule	800 mg	Oral
Subject	Pazopanib	Small molecule	1000 mg	Oral

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications